Role of the epithelial-mesenchymal transition and its effects on embryonic stem cells

Experimental and Molecular Medicine

Volumn 46, Issue 8, 2014, Pages

  Kim, Ye Seul ^a   Yi, Bo Rim ^a   Kim, Nam Hyung ^a   Choi, Kyung Chul ^a  

^a Chungbuk National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; E BOX BINDING PROTEIN; FIBRONECTIN; GLYCOGEN SYNTHASE KINASE 3BETA; HELIX LOOP HELIX PROTEIN; NOTCH RECEPTOR; PROTEIN TYROSINE KINASE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR ZEB; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN; WNT PROTEIN; CADHERIN;

CELL TRANSFORMATION; CYTOSKELETON; EMBRYO DEVELOPMENT; EMBRYONIC STEM CELL; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIUM CELL; FIBROSIS; HISTOGENESIS; HUMAN; MESENCHYME CELL; NEOPLASM; NONHUMAN; ORGANOGENESIS; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; CYTOLOGY; METABOLISM;

ANIMALS; CADHERINS; EMBRYONIC STEM CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 84906877532     PISSN: 12263613     EISSN: 20926413     Source Type: Journal    
DOI: 10.1038/emm.2014.44     Document Type: Review

References (63)

1. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009; 139: 871-890.
2. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: Acquisition of malignant and stem cell traits. Nat Rev Cancer 2009; 9: 265-273.
3. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009; 119: 1420-1428.
4. Sohal SS, Walters EH. Role of epithelial mesenchymal transition (EMT) in chronic obstructive pulmonary disease (COPD). Respir Res 2013; 14: 120.
5. Rippon HJ, Bishop AE. Embryonic stem cells. Cell Prolif 2004; 37: 23-34.
6. Evans MJ, Kaufman MH. Establishment in culture of pluripotential cells from mouse embryos. Nature 1981; 292: 154-156.
7. Ginis I, Luo Y, Miura T, Thies S, Brandenberger R, Gerecht-Nir S et al. Differences between human and mouse embryonic stem cells. Dev Biol 2004; 269: 360-380.
8. Hanna J, Cheng AW, Saha K, Kim J, Lengner CJ, Soldner F et al. Human embryonic stem cells with biological and epigenetic characteristics similar to those of mouse ESCs. Proc Natl Acad Sci USA 2010; 107: 9222-9227.
9. Nichols J, Smith A. Naive and primed pluripotent states. Cell Stem Cell 2009; 4: 487-492.
10. Park JK, Kim HS, Uh KJ, Choi KH, Kim HM, Lee T et al. Primed pluripotent cell lines derived from various embryonic origins and somatic cells in pig. PLoS ONE 2013; 8: e52481.
11. Mohamet L, Hawkins K, Ward CM. Loss of function of e-cadherin in embryonic stem cells and the relevance to models of tumorigenesis. J Oncol 2011; 2011: 352616.
12. Pertz O, Bozic D, Koch AW, Fauser C, Brancaccio A, Engel J. A new crystal structure, Ca2+ dependence and mutational analysis reveal molecular details of E-cadherin homoassociation. EMBO J 1999; 18: 1738-1747.
13. Perez-Moreno M, Fuchs E. Catenins: keeping cells from getting their signals crossed. Dev Cell 2006; 11: 601-612.
14. Xiong H, Hong J, Du W, Lin YW, Ren LL, Wang YC, et al. Roles of STAT3 and ZEB1 proteins in E-cadherin down-regulation and human colorectal cancer epithelial-mesenchymal transition. J Biol Chem 2012; 287: 5819-5832.
15. Di Croce L, Pelicci PG. Tumour-associated hypermethylation: silencing E-cadherin expression enhances invasion and metastasis. Eur J Cancer 2003; 39: 413-414.
16. Nieto MA. The snail superfamily of zinc-finger transcription factors. Nat Rev 2002; 3: 155-166.
17. Sanchez-Tillo E, Liu Y, de Barrios O, Siles L, Fanlo L, Cuatrecasas M et al. EMT-activating transcription factors in cancer: beyond EMT and tumor invasiveness. Cell Mol Life Sci 2012; 69: 3429-3456.
18. Vandewalle C, Van Roy F, Berx G. The role of the ZEB family of transcription factors in development and disease. Cell Mol Life Sci 2009; 66: 773-787.
19. Xue G, Hemmings BA. Phosphorylation of basic helix-loop-helix transcription factor Twist in development and disease. Biochem Soc Trans 2012; 40: 90-93.
20. Xu J, Lamouille S, Derynck R. TGF-beta-induced epithelial to mesenchymal transition. Cell Res 2009; 19: 156-172.
21. Garg M. Epithelial-mesenchymal transition-activating transcription factors-multifunctional regulators in cancer. World J Stem Cells 2013; 5: 188-195.
22. Jorda M, Olmeda D, Vinyals A, Valero E, Cubillo E, Llorens A et al. Upregulation of MMP-9 in MDCK epithelial cell line in response to expression of the Snail transcription factor. J Cell Sci 2005; 118: 3371-3385.
23. Taki M, Verschueren K, Yokoyama K, Nagayama M, Kamata N. Involvement of Ets-1 transcription factor in inducing matrix metalloproteinase-2 expression by epithelial-mesenchymal transition in human squamous carcinoma cells. Int J Oncol 2006; 28: 487-496.
24. Medici D, Hay ED, Olsen BR. Snail and Slug promote epithelialmesenchymal transition through beta-catenin-T-cell factor-4-dependent expression of transforming growth factor-beta3. Mol Biol Cell 2008; 19: 4875-4887.
25. Peinado H, Olmeda D, Cano A. Snail, Zeb and bHLH factors in tumour progression: An alliance against the epithelial phenotype? Nat Rev Cancer 2007; 7: 415-428.
26. Khan MA, Chen HC, Zhang D, Fu J. Twist: A molecular target in cancer therapeutics. Tumour Biol 2013; 34: 2497-2506.
27. Fu J, Qin L, He T, Qin J, Hong J, Wong J et al. The TWIST/Mi2/NuRD protein complex and its essential role in cancer metastasis. Cell Res 2011; 21: 275-289.
28. Burk U, Schubert J, Wellner U, Schmalhofer O, Vincan E, Spaderna S et al. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep 2008; 9: 582-589.
29. Das S, Becker BN, Hoffmann FM, Mertz JE. Reversal of transforming growth factor-beta induced epithelial-to-mesenchymal transition and the ZEB proteins. Fibrogenesis Tissue Repair 2012; 5(Suppl 1), S28.
30. Thiery JP. Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol 2003; 15: 740-746.
31. Lee J, Choi JH, Joo CK. TGF-beta1 regulates cell fate during epithelialmesenchymal transition by upregulating survivin. Cell Death Dis 2013; 4: e714.
32. Miyazono K. Transforming growth factor-beta signaling in epithelialmesenchymal transition and progression of cancer. Proc Jpn Acad Ser B Phys Biol Sci 2009; 85: 314-323.
33. Yang Y, Pan X, Lei W, Wang J, Song J. Transforming growth factor-beta1 induces epithelial-to-mesenchymal transition and apoptosis via a cell cycle-dependent mechanism. Oncogene 2006; 25: 7235-7244.
34. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 2003; 425: 577-584.
35. Elliott RL, Blobe GC. Role of transforming growth factor Beta in human cancer. J Clin Oncol 2005; 23: 2078-2093.
36. Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004; 117: 927-939.
37. Grady WM. Transforming growth factor-beta, Smads, and cancer. Clin Cancer Res 2005; 11: 3151-3154.
38. Zhang YE. Non-Smad pathways in TGF-beta signaling. Cell Res 2009; 19: 128-139.
39. Miele L. Notch signaling. Clin Cancer Res 2006; 12: 1074-1079.
40. Wang Z, Li Y, Kong D, Sarkar FH. The role of Notch signaling pathway in epithelial-mesenchymal transition (EMT) during development and tumor aggressiveness. Curr Drug Targets 2010; 11: 745-751.
41. Bray SJ. Notch signalling: A simple pathway becomes complex. Nat Rev Mol Cell Biol 2006; 7: 678-689.
42. Noseda M, McLean G, Niessen K, Chang L, Pollet I, Montpetit R et al. Notch activation results in phenotypic and functional changes consistent with endothelial-to-mesenchymal transformation. Circ Res 2004; 94: 910-917.
43. Niessen K, Fu Y, Chang L, Hoodless PA, McFadden D, Karsan A. Slug is a direct Notch target required for initiation of cardiac cushion cellularization. J Cell Biol 2008; 182: 315-325.
44. Timmerman LA, Grego-Bessa J, Raya A, Bertran E, Perez-Pomares JM, Diez J et al. Notch promotes epithelial-mesenchymal transition during cardiac development and oncogenic transformation. Genes Dev 2004; 18: 99-115.
45. MacDonald BT, Tamai K, He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell 2009; 17: 9-26.
46. Rao TP, Kuhl M. An updated overview on Wnt signaling pathways: A prelude for more. Cir Res 2010; 106: 1798-1806.
47. Nawshad A, Medici D, Liu CC, Hay ED. TGFbeta3 inhibits E-cadherin gene expression in palate medial-edge epithelial cells through a Smad2-Smad4- LEF1 transcription complex. J Cell Sci 2007; 120: 1646-1653.
48. Wu Y, Ginther C, Kim J, Mosher N, Chung S, Slamon D et al. Expression of Wnt3 activates Wnt/beta-catenin pathway and promotes EMT-like phenotype in trastuzumab-resistant HER2-overexpressing breast cancer cells. Mol Cancer Res 2012; 10: 1597-1606.
49. Jiang YG, Luo Y, He DL, Li X, Zhang LL, Peng T et al. Role of Wnt/betacatenin signaling pathway in epithelial-mesenchymal transition of human prostate cancer induced by hypoxia-inducible factor-1alpha. Int J Urol 2007; 14: 1034-1039.
50. Wu ZQ, Li XY, Hu CY, Ford M, Kleer CG, Weiss SJ. Canonical Wnt signaling regulates Slug activity and links epithelial-mesenchymal transition with epigenetic Breast Cancer 1, Early Onset (BRCA1) repression. Proc Natl Acad Sci USA 2012; 109: 16654-16659.
51. Ullmann U, Gilles C, De Rycke M, Van de Velde H, Sermon K, Liebaers I. GSK-3-specific inhibitor-supplemented hESC medium prevents the epithelial-mesenchymal transition process and the up-regulation of matrix metalloproteinases in hESCs cultured in feeder-free conditions. Mol Hum Reprod 2008; 14: 169-179.
52. Ullmann U, In't Veld P, Gilles C, Sermon K, De Rycke M, Van de Velde H et al. Epithelial-mesenchymal transition process in human embryonic stem cells cultured in feeder-free conditions. Mol Hum Reprod 2007; 13: 21-32.
53. Eastham AM, Spencer H, Soncin F, Ritson S, Merry CL, Stern PL et al. Epithelial-mesenchymal transition events during human embryonic stem cell differentiation. Cancer Res 2007; 67: 11254-11262.
54. Naganuma H, Kono K, Mori Y, Takayoshi S, Stern PL, Tasaka K et al. Oncofetal antigen 5T4 expression as a prognostic factor in patients with gastric cancer. Anticancer Res 2002; 22: 1033-1038.
55. Starzynska T, Rahi V, Stern PL. The expression of 5T4 antigen in colorectal and gastric carcinoma. Br J Cancer 1992; 66: 867-869.
56. Wrigley E, McGown AT, Rennison J, Swindell R, Crowther D, Starzynska T et al. 5T4 oncofetal antigen expression in ovarian carcinoma. Int J Gynecol Cancer 1995; 5: 269-274.
57. Carsberg CJ, Myers KA, Stern PL. Metastasis-associated 5T4 antigen disrupts cell-cell contacts and induces cellular motility in epithelial cells. Int J Cancer 1996; 68: 84-92.
58. Ward CM, Barrow K, Woods AM, Stern PL. The 5T4 oncofoetal antigen is an early differentiation marker of mouse ES cells and its absence is a useful means to assess pluripotency. J Cell Sci 2003; 116: 4533-4542.
59. Chan DN, Azghadi SF, Feng J, Lowry WE. PTK7 marks the first human developmental EMT in vitro. PLoS ONE 2012; 7: e50432.
60. Yen WW, Williams M, Periasamy A, Conaway M, Burdsal C, Keller R et al. PTK7 is essential for polarized cell motility and convergent extension during mouse gastrulation. Development (Cambridge, England) 2009; 136: 2039-2048.
61. Ahn HJ, Cha Y, Moon SH, Jung JE, Park KS. Ell3 enhances differentiation of mouse embryonic stem cells by regulating epithelial-mesenchymal transition and apoptosis. PLoS ONE 2012; 7: e40293.
62. Gill JG, Langer EM, Lindsley RC, Cai M, Murphy TL, Kyba M et al. Snail and the microRNA-200 family act in opposition to regulate epithelial- tomesenchymal transition and germ layer fate restriction in differentiating ESCs. Stem Cells (Dayton, Ohio) 2011; 29: 764-776.
63. Li R, Liang J, Ni S, Zhou T, Qing X, Li H et al. A mesenchymal-to- epithelial transition initiates and is required for the nuclear reprogramming of mouse fibroblasts. Cell Stem Cell 2010; 7: 51-63.